EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinical Risk Factors for High‐Dose Methotrexate‐Induced Oral Mucositis Following Individualized Dosing

Zhongbo Hu iD, Andrea M Escalera-Joy, Emily Ashcraft, Rushil Acharya iD, Sima Jeha iD, Cheng Cheng, Ching-Hon Pui

Cancer Medicine · 2024

DOI: 10.1002/cam4.70351 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Zhongbo Hu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Hospitalist Medicine Program, Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA. Hauptthemen laut MEDLINE: Antimetabolites, Antineoplastic, Methotrexate, Precision Medicine, Stomatitis. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute Cancer Center Support. CORE Grant, National Cancer Institute pediatric oncology education grant.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Oral mucositis affects about 20% of children undergoing high‐dose methotrexate (HDMTX) for acute lymphoblastic leukemia (ALL), despite existing management strategies. Personalized HDMTX dosing, adjusted by pharmacokinetics and leukemia risk, has reduced mucositis incidence, but variations still occur with similar 24‐h methotrexate levels.

Methods

This retrospective study investigated risk factors for oral mucositis under individualized methotrexate protocols. Data from patients with ≥ Grade 2 oral mucositis (CTCAE v4.0) were analyzed from the St. Jude Children's Research Hospital total 16 trial. A 1:1 case–control matching method considered age, sex, risk classification, immunophenotype, and methotrexate course. McNemar's, Bowker's symmetry, and Wilcoxon signed‐rank tests were used for statistical analyses. Risk factors for recurrent mucositis were identified in a case‐only analysis.

Results

The study found significant associations between methotrexate‐induced mucositis and new‐onset skin rashes ( p = 0.0027), fever ( p = 0.0016), neutropenic fever ( p = 0.0008), lower absolute neutrophil count ( p < 0.0001), acute kidney injury (AKI) ( p = 0.0164), delayed methotrexate clearance ( p = 0.0133), and higher 42‐h methotrexate levels ( p = 0.0179). In the standard/high‐risk group, mercaptopurine dose was also linked to mucositis ( p = 0.0495). Multivariable analysis showed that skin rashes (OR 6.5, p = 0.0016), fever (OR 2.8, p = 0.009), and neutropenia (OR 2.3, p = 0.0106) were independent risk factors for mucositis. Female sex (OR 7.12, p = 0.015) and AKI (OR 3.819, p = 0.037) were associated with recurrent mucositis.

Conclusions

Fever, skin rashes, AKI, delayed methotrexate clearance, and higher 42‐h methotrexate levels were key risk factors for HDMTX‐induced oral mucositis. Skin rashes, fever, and neutropenia were independent predictors, while female sex and AKI were linked to recurrent mucositis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antimetabolites, AntineoplasticMethotrexatePrecision MedicineStomatitisChildChild, PreschoolHumansInfantMaleCase-Control StudiesPrecursor Cell Lymphoblastic Leukemia-LymphomaRecurrenceRetrospective StudiesRisk FactorsFemale

Stichwörter der Autor:innen

acute kidney injuryacute lymphoblastic leukemiadelayed methotrexate clearancehigh‐dose methotrexateoral mucositisrisk factors

Substanzen

Antimetabolites, AntineoplasticMethotrexate

Autor:innen und Institutionen

  • Hospitalist Medicine Program, Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
  • Pediatric Oncology Education Program 2023, School of Medicine, Ponce Health Sciences University, Ponce, Puerto Rico.
  • Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
  • Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
  • Department of Global Pediatric Medicine, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
  • Department of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.

ORCID-Profile: Zhongbo Hu, Rushil Acharya, Sima Jeha

Förderung

  • NCI NIH HHS
  • National Cancer Institute Cancer Center Support. CORE Grant
  • National Cancer Institute pediatric oncology education grant

Zitieren

APA

Hu, Z., Escalera-Joy, A. M., Ashcraft, E., Acharya, R., Jeha, S., Cheng, C., & Pui, C. H. (2024). Clinical Risk Factors for High‐Dose Methotrexate‐Induced Oral Mucositis Following Individualized Dosing. Cancer Medicine. https://doi.org/10.1002/cam4.70351

Vancouver

Hu Z, Escalera-Joy AM, Ashcraft E, Acharya R, Jeha S, Cheng C, et al. Clinical Risk Factors for High‐Dose Methotrexate‐Induced Oral Mucositis Following Individualized Dosing. Cancer Medicine. 2024. doi:10.1002/cam4.70351

BibTeX
@article{Hu2024,
  author = {Hu, Zhongbo and Escalera-Joy, Andrea M and Ashcraft, Emily and Acharya, Rushil and Jeha, Sima and Cheng, Cheng and Pui, Ching-Hon},
  title = {Clinical Risk Factors for High‐Dose Methotrexate‐Induced Oral Mucositis Following Individualized Dosing},
  journal = {Cancer Medicine},
  year = {2024},
  doi = {10.1002/cam4.70351}
}
Kostenlos starten →